Articles related to Internal Medicine

Baseline cognitive performance predicted future depression risk in opposite directions depending on depression history: lower cognition signaled higher risk in never-depressed controls, while higher cognition was associated with greater relapse risk in remitted depression, in a longitudinal UK Biobank analysis of 3,724 participants.

A middle-aged woman with a four-year bipolar disorder diagnosis continued deteriorating despite psychiatric treatment until clinical reassessment pointed toward anti-NMDA receptor encephalitis, an autoimmune condition whose psychiatric prodrome frequently delays correct diagnosis.

In a 794-patient randomized trial, early-stage type 2 diabetes patients uncontrolled on metformin who received tirzepatide achieved nearly twice the HbA1c reduction of those on intensified conventional care at 2 years, and 60% reached normoglycemia (HbA1c <5.7%), compared to 24% in the ICC arm.

An Oregon gastroenterology group was hit with a $25M wrongful death verdict after a 43-year-old patient with obesity, obstructive sleep apnea, and hypertension died during a routine outpatient colonoscopy, with liability centered on the decision to perform the procedure in a lower-acuity setting despite a risk profile that plaintiffs argued warranted a hospital environment.

Phase 3 TRIUMPH-1 trial results for retatrutide, a triple hormone agonist targeting GIP, GLP-1, and glucagon receptors, showed up to 28.3% mean weight loss at 80 weeks and 30.3% in patients with BMI ≥35 at 104 weeks — the largest weight reduction reported in a medication trial to date, per Lilly’s press release.

Two Lilly-sponsored placebo-controlled trials found that adults who transitioned from high-dose injectable GLP-1 therapy to either oral tirzepatide (Foundayo) or a reduced 5 mg tirzepatide maintenance dose preserved most of their prior weight loss over one year, compared to substantial regain in placebo arms.